Stem Cell Therapy for Multiple Sclerosis Global Market Report 2025

The stem cell therapy for multiple sclerosis market size has grown rapidly in recent years. It will grow from $1.62 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be linked to increasing demand for regenerative medicine, a rising prevalence of multiple sclerosis, growing awareness of stem cell therapies, increasing investment in stem cell research, and improving clinical outcomes demonstrating the effectiveness of stem cell therapy.

The stem cell therapy for multiple sclerosis market size is expected to see rapid growth in the next few years. It will grow to $2.89 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be driven by rising demand for personalized medicine, growing patient preference for minimally invasive treatments, the expansion of regenerative therapy centers, increasing insurance coverage for advanced treatments, and strengthening collaborations between biotech companies and research institutions. Major trends in the forecast period include technological advancements in stem cell delivery methods, progress in gene editing and regenerative techniques, innovations in immunomodulatory therapies, increased research and development investment for novel treatments, and advancements in biomaterials supporting cell therapy.

The growing prevalence of multiple sclerosis (MS) is expected to significantly contribute to the expansion of the stem cell therapy market for multiple sclerosis in the future. Multiple sclerosis is a chronic autoimmune condition that affects the central nervous system by damaging the protective myelin sheath around nerve fibers, leading to disrupted communication between the brain and the body, and causing symptoms such as fatigue, muscle weakness, and vision problems. The rising number of MS cases is mainly due to advancements in diagnostic techniques, as improvements in medical imaging and increased awareness allow for more accurate and earlier detection, resulting in a higher number of reported cases. Stem cell therapy for multiple sclerosis helps repair damaged myelin, modulate abnormal immune responses, and encourage nerve cell regeneration, potentially reducing symptoms and slowing disease progression. For example, in May 2024, the MS Trust, a UK-based organization, published a report stating that approximately 2.9 million people worldwide are affected by multiple sclerosis, with over 150,000 individuals in the UK living with the condition. Therefore, the increasing prevalence of multiple sclerosis is expected to drive the growth of the stem cell therapy market for multiple sclerosis.

Leading companies in the stem cell therapy for multiple sclerosis market are focusing on developing innovative treatments, such as adipose-derived mesenchymal stem cells, to improve the efficacy, safety, and regenerative potential of therapies for patients with relapsing-remitting and progressive forms of multiple sclerosis. Adipose-derived mesenchymal stem cells (ADMSCs) are multipotent stem cells obtained from adipose (fat) tissue that can differentiate into various cell types and possess regenerative and immunomodulatory properties that are beneficial in treating autoimmune and neurodegenerative diseases like multiple sclerosis. For instance, in August 2025, Hope Biosciences, LLC, a U.S.-based biopharmaceutical company, introduced its HB-adMSCs therapy, which uses adipose-derived mesenchymal stem cells administered via high-dose infusions and repeat dosing over a 32-week period. The therapy combines immunomodulatory and neuroregenerative mechanisms, offering the potential to slow disease progression and repair myelin damage, setting it apart from conventional immunosuppressive treatments.

In November 2024, Pluri Inc., an Israel-based biotechnology company, partnered with Brainstorm Cell Therapeutics Ltd. Through this collaboration, Pluri Inc. aims to advance the development and commercialization of innovative regenerative therapies in partnership with Brainstorm Cell Therapeutics, combining their expertise to accelerate clinical research and improve treatment outcomes for patients. Brainstorm Cell Therapeutics Ltd. is a U.S.-based biotechnology company that specializes in stem cell therapy for multiple sclerosis.

Major companies operating in the stem cell therapy for multiple sclerosis market are Sana Biotechnology Inc., Century Therapeutics Inc., Reelabs Private Limited, PlacidWay LLC, MedAccess Guarantee Ltd, Celltex Therapeutics Corporation, CELLTEX THERAPEUTICS CORP, BrainStorm Cell Therapeutics Ltd., Athersys Inc., Advancells Dermaceuticals Private Limited, ImStem Biotechnology Inc., NeuroGenesis Bio Inc., Stem Cell Medicine Ltd., Biotherapy International, R3 Stem Cell, Hope Biosciences LLC, FibroBiologics Inc., Global Institute of Stem Cell Therapy and Research Inc., ProgenCell, Stemwell

North America was the largest region in the stem cell therapy for multiple sclerosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stem cell therapy for multiple sclerosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the stem cell therapy for multiple sclerosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The stem cell therapy for multiple sclerosis market research report is one of a series of new reports that provides stem cell therapy for multiple sclerosis market statistics, including stem cell therapy for multiple sclerosis industry global market size, regional shares, competitors with a stem cell therapy for multiple sclerosis market share, detailed stem cell therapy for multiple sclerosis market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy for multiple sclerosis industry. This stem cell therapy for multiple sclerosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell therapy for multiple sclerosis is a regenerative medical treatment that uses stem cells to repair nerve damage and restore immune system balance in individuals with multiple sclerosis, an autoimmune disease that attacks the myelin sheath protecting nerve fibers. The therapy aims to halt disease progression, reduce inflammation, and support the regeneration of damaged nervous tissue.

The main components of stem cell therapy for multiple sclerosis include embryonic stem cells, adult stem cells, induced pluripotent stem cells, mesenchymal stem cells, and hematopoietic stem cells. Stem cell therapy for multiple sclerosis using embryonic stem cells involves transplanting pluripotent cells derived from early-stage embryos to repair damaged myelin and promote neural regeneration. Treatment approaches include autologous stem cell therapy and allogeneic stem cell therapy. Delivery methods include intravenous injection, intrathecal injection, and direct intraspinal administration. Applications encompass relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), and progressive relapsing multiple sclerosis (PRMS). End users include hospitals, specialty clinics, research institutes, and others.

The stem cell therapy for multiple sclerosis market includes revenues earned by providing services such as stem cell collection and processing services, cryopreservation and storage services, patient preconditioning services, post-therapy rehabilitation services, and immune system profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.